Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $1.4 billion.

  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity rose 21.54% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 48.49%. This contributed to the annual value of $1.4 billion for FY2025, which is 21.54% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $1.4 billion for FY2025, which was up 21.54% from $1.1 billion recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $1.4 billion during FY2025, and its lowest value of $691.9 million during FY2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.1 billion, with a median of $1.1 billion in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first declined by 2.56% in 2022, then spiked by 48.89% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $710.1 million in 2021, then fell by 2.56% to $691.9 million in 2022, then grew by 10.64% to $765.6 million in 2023, then spiked by 48.89% to $1.1 billion in 2024, then climbed by 21.54% to $1.4 billion in 2025.